
YmAbs’ 131I-8H9 Receives EU Orphan Drug Designation 03 March 2017
Y-mAbs Therapeutics, Inc. receives first European Orphan Drug Designation NEW YORK, March 1, 2017 –... Read more

Y-mAbs Therapeutics, Inc. receives first European Orphan Drug Designation NEW YORK, March 1, 2017 –... Read more

Indstillingsskema Novo Nordisk Fondens Gymnasielærerpris 2017 Opslag Novo Nordisk Fondens Gymnasielærerpris... Read more
7 principper for sundhedsdata >>

Biogen will pay Forward a non-refundable cash fee of $1.25 billion Forward may be eligible to receive... Read more

Y-mAbs Therapeutics, Inc. closes $12 million in private placement among current shareholders NEW YORK,... Read more

Det danske biotekselskab Minervax melder om positive resultater fra et fase 1-forsøg med dets vaccine... Read more

IO Biotech develops novel therapeutic immuno-oncology vaccines targeting immune check point inhibitory... Read more

Join us in New York to meet with top investors, pharma & partners hosted at Citi Headquarters. -Special... Read more

Novo Nordisk Fondens Gymnasielærerpris blev indstiftet i 2014 af DANISH BIO – DANSK BIOTEK og ... Read more